Dr. Jaganmohan has completed his Ph.D from Kakatiya University, India and Postdoctoral studies from Florida A&M University. More than 25 papers & 50 presentations at national and international level and two books are in his credit. Dr. Jagan is also a subject matter expert, scientific speaker and consultant for clinical trial designs with more than one decade of research experience in India and USA.

Currently he is a senior research scientist heading Pharmacokinetics, Bio-statistics & Medical Writing departments for BA/BE and Phase trails in ClinSync Clinical CRO, India

Dr. Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years and is the contributing author for Kaplan Medical’s Pharmacology Review Book. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.

His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complimentary and Alternative medicine is another area of interest.

Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. . He was Prof of Biology at University of Colorado and Visiting Prof of Medical Oncology at University of Texas. He is Research Associate at Harvard TH Chan School of Public Health and Honorary Reader at University College London. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Springer-Nature book on a breast cancer project published July 2017. After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic adjuvant chemotherapy. He is a founder and for 10 years was on the Board of Directors of the Colon Cancer Alliance. He has published more than 70 papers in physics and cancer.

Research interest A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia, studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer, Using computer simulation and access to a very high quality database from Milan for patients treated with mastectomy only.

Dr. Alain L Fymat is a medical-physical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles) and has lectured extensively in the USA, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 25 scientific Journals

Dr. Fymat’s current research interests lie at the interface between science and medicine, particularly cancer/oncology, molecular/personal/precision medicine, nanomedicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics. His most recent publications deal with nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.

Esmaiel Jabbari is Full Professor of Chemical Engineering at University of South Carolina. He is internationally known for his work on synthesis and processing of biomimetic bio inspired materials for drug delivery and tissue engineering applications. His research interests include bio inspired materials, skeletal tissue engineering, stem cell encapsulation and delivery, self-assembled nanogels for growth factor delivery, drug targeting to cancer stem cells, and engineering the microenvironment of cancer cells. He has published extensively in the areas of biomaterials, drug delivery, and tissue engineering. He has edited four books, published two encyclopedia entry, 20 book chapters, over 110 refereed journal papers, over 100 refereed conference proceedings, presented over 60 invited seminars, and >200 presentations at national and International conferences. He received his PhD in Biomaterials from Purdue under the supervision of Professor Nicholas A. Peppas and his Masters degrees, in chemical engineering and chemistry, and his undergraduate degree in Chemical Engineering from Virginia Tech.

Tissue engineering, bio-mimetic materials, bio-inspired nano-composites, peptide-mediated drug delivery.

Dr. GIULIO TARRO is currently working as a Professor in the Department of Department of Biology, Temple University , USA. His research interests includes human herpesviruses, virus-induced tumour antigens. He is serving as an editorial member and reviewer of several international reputed journals. Dr. GIULIO TARRO is the member of many international affiliations. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to human herpesviruses, virus-induced tumour antigens

His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the “finger-prints” left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Dr. Debabrata Mukhopadhyay is a Professor of Biochemistry and Molecular Biology and Director of both Tumor Microenvironment and Nanomedicine programs, at the Mayo Clinic, Rochester, MN. He has a joint appointment with the Department of Physiology and Biomedical Engineering and Associate Director of Mayo Clinic Comprehensive Cancer Center for Global Alliances. Prior to joining Mayo Clinic, he was an Associate Professor at Harvard Medical School, Boston, where he carried out angiogenesis and tumor microenvironment related research. Dr. Mukhopadhyay’s expertise lies in Tumor Biology, Nanomedicine and other key research areas such as Cancer, Cardiovascular Diseases, and Diabetes. In this interview, he gives career guidance and advice to students interested in pursuing a career in Tumor Biology, Cancer research, Nanotechnology and Nanomedicine.

Microbiology,Immunology,Biochemistry,Renal Cancer, Cardiovascular Diseases, and Diabetes.

Fabio Geremia, graduated in Pharmaceutical Chemistry, Qualified Person; he has worked in italian and multinational pharmaceutical companies, in Quality and Production field. 10 years ago he joined CTP System group, the biggest italian company of pharmaceuticals, healthcare and life science consultancy, now part of the multinational group Akka Technologies, where he is a senior consultant and a Qualified Person auditor and the technical responsible for Process & Quality Business Area, Northern Italy. Since many years he collaborates with the italian association AFI for medical devices and borderline products, for the preparation of publications and presentations.

GMP,Pharmaceutical Industry,GxP,Validation,FDA,21 CFR,Computer System Validation,Quality System,Cleaning Validation,SOP,GAMP,CAPA,U.S. Food and Drug Administration (FDA),Standard Operating Procedure (SOP).

Heike Schoen is the Managing Director and Co-Founder of LUMIS International GmbH, headquartered in Germany. With her company she has specialized to support Biotech and Medical Device companies to implement clinical processes to cope with the regulatory requirements to perform effective oversight management of their clinical trials. The company also offers legal representation for non-European Sponsors. She has worked in leading positions in clinical research for more than 20 years. Her experience ranges from conducting national and international Phase I clinical trials all the way to registration and post marketing activities as well as business development within contract research organizations (CROs) and the biotechnology industry. Her previous positions included operational and general management in clinical research. She holds a master’s degree in psychology and a master’s degree in business administration.

Transition from pre-clinical to clinical development, optimizing clinical research processes through effective vendor selection and oversight management of clinical trials

Dr. Jorge Gonzalez Borroto (Phar.D., Ph.D) is Senior Nonclinical Toxicologist and Pharmacovigilance Officer in the pharmaceutical company Ferrer International S.A., Barcelona, Spain. He accomplished his Ph.D in Genetic, specialization in Genetic Toxicology from Autonomous University of Barcelona (UAB, Barcelona, Spain). He has been involved in development of new testing strategies for predictive toxicology through validation of novel tests and cell-based assays in drug discovery, development of new biomarkers for assessment of toxicological effects in animal models and integration of in vitro and in vivo safety results during drugs development to obtain safer drugs for human use.

Nonclinical Toxicology, Safety Assessment and Pharmacovigilance.

Jianguo Yang has nearly 20 years of international biopharma industry experience, including in Abbott Lab ( current Abbiev), MedImmune/Astrozeneca, Genzyme/Sanofi in US and, recently VP/CSO in Qilu Pharmaceutical. As international recognized expert in bioprocess, he achieved world record of high mammalian cell line productivity and published numerous patents and papers. He is an Editorial Advisor and Reviewer of Bioprocess International (Journals), and Executive Director, Sino-America Pharmaceutical Association (SAPA), and reviewer for scientific journals, and a frequently-invited speaker for international conferences. He got his PhD in Cell/Molecular Biology from IlIinois Institute of Technology, US

Biosimilars, Biologics, Biotechnology, Molecular Biology, Protein Purification,GMP.

Jun Xu, PhD, Professor in Medicinal Chemistry & CADD, Director and Founder of Research Center for Drug Discovery (RCDD) and the HPC Center for Life Sciences (HPCCLS), Principal Investigator of School of Pharmaceutical Sciences at Sun Yat-sen University. He received PhD degree in Chemistry from University of Science & Technology of China in 1989, finished his post-doc training in Protein NMR from Australian National University (ANU) and McGill University in Montreal.

High performance computer (HPC) algorithms for drug design, Chemomics and drug innovation, Structure Biology, Computer-aided drug design (CADD) and applications, Quantum Medicinal Chemistry, Drug lead identification and optimization based upon natural products and quasi-natural products, Chemo informatics and bioinformatics applied in the design of targeted drugs and traditional Chinese medicine (TCM) remedies.

Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy

Dr. Kang Choon Lee is Haengdan Distinguished Professor at the SungKyunKwan University (SKKU), Korea, and was director of the Center of Excellence for Future Pharmaceutical Education and Research in the College of Pharmacy at SKKU. He served as a professor and dean at the College of Pharmacy as well as the director of the Institute of Pharmaceutical Science. Prior to joining SKKU in 1992, Dr. Lee was a principal scientist at Dong-A Pharmaceutical Co. for ten years before joining Chonnam National University as a professor of pharmacy. For over 30 years, Dr. Lee’s Drug Targeting Laboratory has been focused on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs. Dr. Lee is internationally recognized as one of the leading experts in site-specific peptide/protein PEGylation and firstly demonstrated the therapeutic potential of novel site-specific PEGylated drugs such as GLP-1 and TRAIL. He has published over 150 papers in peer-reviewed journals and served as an invited speaker at many international conferences. Dr. Lee is an inventor on more than 20 patents related to specific bioconjugation and modification of peptide/protein drugs. He served as president of the Korean-American Pharmaceutical Scientists Association and vice-president of the Pharmaceutical Society of Korea and Korean Society of Pharmaceutical Science and Technology. Dr. Lee is a recipient of the Distinguished Pharmaceutical Scientist Award from the Pharmaceutical Society of Korea in 2002 and honored as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2003. He currently serves on the editorial advisory board of many international scientific journals including Pharmaceutical Research, Pharmaceutical Development and Technology, PharmSciTech, Journal of Drug Delivery and Heliyon. For clinically translating and commercializing of site-specific PEGylated peptide/protein drugs developed by his laboratory, he co-founded B&L DeliPharm, Korea and Theraly Pharmaceuticals, USA.

on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs

Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium Pharmaceuticals, Martinsried, Germany, and at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim manager, Dr. Mudde co-founded the biotech company f-star Biotechnology. In 2009, together with Christof Langer, he started to develop the S-TIR™ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget therapeutics GmbH in 2010, and the spin-off companies OncoQR ML GmbH (2013) and TYG oncology Ltd. (2013). Dr Mudde serves as CSO and managing director for OncoQR ML

Therapeutic vaccination with immune check point control